Skip to main content

Advertisement

SpringerLink
Log in

The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Dramatic progress in the treatment of childhood acute lymphoblastic leukemia (ALL) has been achieved during the last two decades in Western countries, where the 5-year event-free survival (EFS) rate has risen from 30 to 85 %. However, similarly high cure rates have not always been achieved in all centers in developing countries due to limited sources. We evaluated the treatment results of the ALL-Berlin–Frankfurt–Münster (BFM) 95 protocol as used between 1995 and 2009 in the pediatric hematology departments of two university hospitals. A retrospective analysis of 343 children newly diagnosed with ALL (M/F 200/143, median age 6.8 years) was performed. The overall survival (OS) and EFS according to age, initial leukocyte count, immunophenotype, chemotherapy responses (on days 8, 15, and 33), and risk groups were analyzed by Kaplan–Meier survival analysis. Median follow-up time was 6.4 years. Complete remission was achieved in 97 % of children. Five-year EFS and OS were found to be 78.4 and 79.9 %, respectively. Children younger than 6 years old had significantly better EFS and OS (83.7 and 85.2 %) than children aged ≥6 years (71.4 and 72.8 %). Adolescents achieved 63 % EFS and 65 % OS. Patients who had initial leukocyte counts of <20 × 109/L had better EFS and OS (82.2 and 84.6 %) than children with higher initial leukocyte counts (72.6 and 72.6 %). EFS for B-cell precursor and T-cell ALL was 81.5 and 66.7 %, respectively. Children with a good response to prednisolone on day 8 (87 %) achieved significantly better EFS and OS (81.2 and 81.9 % vs. 55.3 and 60.5 %). Children whose bone marrow on day 15 was in complete remission had higher EFS and OS (83.7 and 86.6.1 % vs. 56.4 and 61.5 %). Children in the standard-risk and medium-risk groups obtained statistically significantly higher EFS (95.5 and 82.7 %) and OS (97.7 and 82.3 %) compared to the high-risk group (EFS 56.3 %, OS 63.4 %). The relapse rate was 14.8 %. The median relapse time from diagnosis was 23.2 months. Death occurred in 69 of 343 patients (20.1 %). The major causes of death were infection and relapse. None of the patients died of drug-related toxicity. The ALL-BFM 95 protocol was applied successfully in these two centers. In developing countries in which minimal residual disease cannot be monitored, this protocol can still be used with high survival rates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention (CDC) (2007) Trends in childhood cancer mortality—United States, 1990–2004. MMWR Morb Mortal Wkly Rep 56(48):1257–1261

    Google Scholar 

  2. Linabery AM, Ross JA (2008) Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer 112(2):416–432

    Article  PubMed  Google Scholar 

  3. Schrappe M, Nachman J, Hunger S, Schmiegelow K, Conter V, Masera G, Pieters R, Pui CH (2010) Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000). Leukemia 24(2):253–254

    Article  CAS  PubMed  Google Scholar 

  4. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood 97(5):1211–1218

    Article  CAS  PubMed  Google Scholar 

  5. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M, German-Austrian-Swiss ALL-BFM Study Group (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM95. Blood 1111(9):4477–4489

    Article  Google Scholar 

  6. Pui CH, Mullighan CG, Evans WE, Relling MV (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 120:1165–1174

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Marwaha RK, Kulkarni RP, Bansal D, Trehan A (2010) Pattern of mortality in childhood acute lymphoblastic leukemia: experience from a single center in northern India. J Pediatr Hematol Oncol 32(5):366–369

    Article  PubMed  Google Scholar 

  8. Metzger ML, Howard SC, Fu LC, Peña A, Stefan R, Hancock ML, Zhang Z, Pui CH, Wilimas J, Ribeiro RC (2003) Outcome of childhood acute lymphoblastic leukemia in resource-poor countries. Lancet 362(9385):706–708

    Article  PubMed  Google Scholar 

  9. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14(12):2205–2222

    Article  CAS  PubMed  Google Scholar 

  10. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24(2):265–284

    Article  PubMed  Google Scholar 

  11. Hazar V, Karasu GT, Uygun V, Akcan M, Küpesiz A, Yesilipek A (2010) Childhood acute lymphoblastic leukemia in Turkey: factors influencing treatment and outcome: a single center experience. J Pediatr Hematol Oncol 32(8):e317–e322

    Article  PubMed  Google Scholar 

  12. Von Stackelberg A, Karatchunsky A, Kudrjashova J, Miakova N, Belikova L, Rumiantzev A, Hartmann R, Henze G (1999) Toxicity supportive care and costs of two chemotherapy protocols for treatment of childhood ALL in Russia: BFM 90m and MB 91. Eur J Cancer 35(9):1349–1355

    Article  Google Scholar 

  13. Campbell M, Salgado C, Quintana J, Becker A, Vargas L, Cabrera ME, Beresi V, Rojas J, Paez E, Tapia S, Zolezzi P, Advis P (1999) Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87. Med Pediatr Oncol 33(2):88–94

    Article  CAS  PubMed  Google Scholar 

  14. Aziz Z, Zahid M, Mahmood R, Maqbool S (1997) Modified BFM protocol for childhood acute lymphoblastic leukemia: a retrospective analysis. Med Pediatr Oncol 28(1):48–53

    Article  CAS  PubMed  Google Scholar 

  15. Bajel A, George B, Mathews V, Viswabandya A, Kavitha ML, Srivastava A, Chandy M (2008) Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer 51(5):621–625

    Article  PubMed  Google Scholar 

  16. İrken G, Ören H, Gülen H, Duman M, Uçar C, Atabay B, Yilmaz S, Uysal K, Cevik N (2002) Treatment outcome of adolescents with acute lymphoblastic leukemia. Ann Hematol 81(11):641–645

    Article  PubMed  Google Scholar 

  17. Kocak U, Gursel T, Kaya Z, Aral YZ, Albayrak M, Keskin EY, Belen B, Isık M, Oner N (2012) ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia—experience of a single center. Pediatr Hematol Oncol 29(2):130–140

    Article  CAS  PubMed  Google Scholar 

  18. Soycan LY, Aydoğan G, Timur Ç, Vergin C, Patıroğlu T, Tanyeli A, Hazar V, Atabay B, Antmen B, Sarper N (2008) Pediatrik ALL tedavisinde ilk çok merkezli tedavi protokolü: BFM-TR ALL 2000. Abstract. 34th National Hematology Conference, Çeşme, İzmir, Turkey (in Turkish)

  19. Pui CH, Pei D, Sandlund JT, Rubnitz JE, Raimondi SC, Onciu M, Campana D, Kun LE, Jeha S, Cheng C, Howard SC, Metzger ML, Bhojwani D, Downing JR, Evans WE, Relling MV (2010) Long-term results of St Jude Total Therapy studies 11, 12, 13A, 13B and 14 for childhood acute lymphoblastic leukemia. Leukemia 24(2):371–382

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Stark B, Nirel R, Avrahami G, Abramov A, Attias D, Ballin A, Bielorai B, Burstein Y, Gavriel H, Elhasid R, Kapelushnik J, Sthoeger D, Toren A, Wientraub M, Yaniv I, Izraeli S (2010) Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98. Leukemia 24(2):419–424

    Article  CAS  PubMed  Google Scholar 

  21. Hussein H, Sidhom I, Naga SA, Amin M, Ebied E, Khairy A, Kamel A, El-Sharkawy N (2004) Outcome and prognostic factors of acute lymphoblastic leukemia in children at the National Cancer Institute, Egypt. J Pediatr Hematol Oncol 26(8):507–514

    Article  PubMed  Google Scholar 

  22. Kulkarni KP, Marwaha RK, Trehan A, Bansal D (2009) Survival outcome in childhood ALL: experience from a tertiary care center in North India. Pediatr Blood Cancer 53(2):168–173

    Article  CAS  PubMed  Google Scholar 

  23. Campana D (2012) Minimal residual disease monitoring in childhood acute lymphoblastic leukemia. Curr Opin Hematol 19(4):313–318

    Article  CAS  PubMed  Google Scholar 

  24. Conter V, Venn NC, Tolisano J, Schrauder A, Panzer-Grümayer R, Möricke A, Aricò M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115(16):3206–3214

    Article  CAS  PubMed  Google Scholar 

  25. Schrappe M, Möricke A, Reiter A, Henze G, Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Gruhn B, Niemeyer C, Kremens B, Niggli F, Debatin KM, Ratei R, Stanulla M, Beier R, Cario G, Schrauder A, Zimmermann M (2013) Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr 225(Suppl 1):62S–72S

    Google Scholar 

  26. Schrappe M (2013) Novel treatment approaches for acute lymphoblastic leukemia in childhood and adolescence. Hematol Educ: Educ Program Annu Congr Eur Hematol Assoc 7:16–22

    Google Scholar 

  27. Hunger SP, Baruchel A, Biondi A, Evans WE, Jeha S, Loh M, Moericke A, Pieters R, Relling MV, Schmiegelow K, Schrappe M, Silverman LB, Stanulla M, Valsecchi MG, Vora A, Pui CH (2013) The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7–9, 2011. Pediatr Blood Cancer 60(2):344–348

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, Faculty of Medicine, Uludağ University, Bursa, Turkey

    Adalet Meral Güneş, Birol Baytan & Melike Sezgin Evim

  2. Department of Pediatric Hematology, Faculty of Medicine, Dokuz Eylül University, 35340, Balcova, İzmir, Turkey

    Hale Ören, Şebnem Yılmaz Bengoa, Salih Gözmen, Özlem Tüfekçi, Tuba Hilkay Karapınar & Gülersu İrken

Authors
  1. Adalet Meral Güneş
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hale Ören
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birol Baytan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Şebnem Yılmaz Bengoa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Melike Sezgin Evim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Salih Gözmen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Özlem Tüfekçi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tuba Hilkay Karapınar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gülersu İrken
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hale Ören.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Güneş, A.M., Ören, H., Baytan, B. et al. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Ann Hematol 93, 1677–1684 (2014). https://doi.org/10.1007/s00277-014-2106-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2106-0

Keywords

Search

Navigation